...
首页> 外文期刊>Journal of pharmacokinetics and pharmacodynamics >Model-based meta-analysis for development of a population-pharmacokinetic (PPK) model for Vitamin D3 and its 25OHD3 metabolite using both individual and arm-level data
【24h】

Model-based meta-analysis for development of a population-pharmacokinetic (PPK) model for Vitamin D3 and its 25OHD3 metabolite using both individual and arm-level data

机译:基于模型的荟萃分析,使用个体和臂级数据开发维生素D3及其25OHD3代谢物的群体药代动力学(PPK)模型

获取原文
获取原文并翻译 | 示例
           

摘要

Clinical studies investigating relationships between D3 and 25OHD3 vary in dosing regimen, assays, demographics, and control of exogenous D3. This leads to uncertain and conflicting exposure-related associations with D3 and 25OHD3. To elucidate this parent-metabolite system, a PPK model was developed to predict mean D3 and 25OHD3 exposure from varied doses and administration routes. Sources of exposure variability related to metabolite baseline, weight, and assay type were explored. Specific search criteria were used in PUBMED to identify public source PK data pertaining to D3 and 25OHD3 in healthy or osteoporotic populations. Overall 57 studies representing 5395 individuals were selected, including 25 individual-level profiles and treatment-arm data. IV, oral, single and multiple dose data were used, with D3 and 25OHD3 dosing. A nonlinear mixed effects model was developed to simultaneously model PK dispositions of D3 and 25OHD3 (NONMEM v7.2), which were described by 2-compartment models with nonlinear and linear clearances, respectively. Proportional and additive assay variances were included on the 25OHD3 prediction. Unit-level random effects were weighted by treatment-arm size. D3 model estimates, relative to bioavailability were: maximum rate of metabolism (Vmax, 1.62 nmol/h), Michaelis-Menten constant (Km, 6.39 nmol/L), central volume of distribution (Vc, 15.5 L), intercompartmental clearance (Q, 0.185 L/h), peripheral volume of distribution (Vp, 2333 L/h), and baseline concentration (DBASE, 3.75 nmol/L). For 25OHD3 (m = metabolite): CLm = 0.0153 L/h, Vcm = 4.35 L, Vpm = 6.87 L, Qm = 0.0507 L/h. Simulations of 25OHD3 concentration indicated an inverse relationship between 25OHD3 baseline and response, as well as a less than proportional 25OHD3 response. Estimation of assay bias parameters suggested that HPLC-MS and RIA produced similar measurement results, whereas CPBA and CHEMI are over-predictive of 25OHD3 concentration, relative to HPLC-MS.
机译:研究D3和25OHD3之间关系的临床研究在外源D3的给药方案,测定,人口统计学和控制方面有所不同。这导致与D3和25OHD3的暴露相关的不确定和冲突的关联。为了阐明该母体-代谢系统,开发了一种PPK模型来预测不同剂量和给药途径对D3和25OHD3的平均暴露。探索了与代谢物基线,体重和试验类型有关的暴露变异性的来源。在PUBMED中使用特定的搜索标准来识别与健康或骨质疏松人群中D3和25OHD3有关的公共来源PK数据。总共选择了代表5395个人的57项研究,包括25个人水平的资料和治疗组数据。 IV,使用口服,单次和多次剂量数据,并使用D3和25OHD3剂量。开发了一个非线性混合效应模型来同时模拟D3和25OHD3的PK布置(NONMEM v7.2),分别由具有非线性和线性间隙的2舱模型描述。比例和加性分析方差包括在25OHD3预测中。单位水平的随机效应由治疗臂大小加权。 D3模型相对于生物利用度的估计值是:最大代谢速率(Vmax,1.62 nmol / h),Michaelis-Menten常数(Km,6.39 nmol / L),分布的中心体积(Vc,15.5 L),室间清除率(Q ,0.185 L / h),外围分布体积(Vp,2333 L / h)和基线浓度(DBASE,3.75 nmol / L)。对于25OHD3(m =代谢物):CLm = 0.0153 L / h,Vcm = 4.35 L,Vpm = 6.87 L,Qm = 0.0507 L / h。 25OHD3浓度的模拟表明25OHD3基线与响应之间呈反比关系,并且25OHD3响应小于比例。分析偏倚参数的估计表明,HPLC-MS和RIA产生相似的测量结果,而CPBA和CHEMI相对于HPLC-MS过度预测25OHD3浓度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号